Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats

Robert N. Willette, Nambi Aiyar, Tian-Li Yue, Marcus P. Mitchell, Jyoti Disa, Barbara L. Storer, Diane P. Naselsky, Jeffery M. Stadel, Eliot H. Ohlstein and Robert R. Ruffolo Jr.
Journal of Pharmacology and Experimental Therapeutics April 1999, 289 (1) 48-53;
Robert N. Willette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nambi Aiyar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tian-Li Yue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus P. Mitchell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jyoti Disa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara L. Storer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane P. Naselsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffery M. Stadel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliot H. Ohlstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert R. Ruffolo Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Clinical studies conducted with carvedilol suggest that β-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure. However, many β-adrenoceptor antagonists are weak partial agonists and possess significant intrinsic sympathomimetic activity (ISA), which may be problematic in the treatment of heart failure. In the present study, the ISAs of bucindolol, xamoterol, bisoprolol, and carvedilol were evaluated and compared in normal rats [Sprague-Dawley (SD)], in rats with confirmed heart failure [spontaneously hypertensive heart failure (SHHF)], and in isolated neonatal rat cardiomyocytes. At equieffective β1-adrenolytic doses, the administration of xamoterol and bucindolol produced a prolonged, equieffective, and dose-related increase in heart rate in both pithed SD rats (ED50 = 5 and 40 μg/kg, respectively) and SHHF rats (ED50 = 6 and 30 μg/kg, respectively). The maximum effect of both compounds in SHHF rats was approximately 50% of that observed in SD rats. In contrast, carvedilol and bisoprolol had no significant effect on resting heart rate in the pithed SD or SHHF rat. The maximum increase in heart rate elicited by xamoterol and bucindolol was inhibited by treatment with propranolol, carvedilol, and betaxolol (β1-adrenoceptor antagonist) but not by ICI 118551 (β2-adrenoceptor antagonist) in neonatal rat. When the β-adrenoceptor-mediated cAMP response was examined in cardiomyocytes, an identical partial agonist/antagonist response profile was observed for all compounds, demonstrating a strong correlation with the in vivo results. In contrast, GTP-sensitive ligand binding and tissue adenylate cyclase activity were not sensitive methods for detecting β-adrenoceptor partial agonist activity in the heart. In summary, xamoterol and bucindolol, but not carvedilol and bisoprolol, exhibited direct β1-adrenoceptor-mediated ISA in normal and heart failure rats.

Footnotes

  • Send reprint requests to: Robert N. Willette, Ph.D, Department of Cardiovascular Pharmacology, UW2510, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406. E-mail:robert_n_willette{at}sbphrd.com

  • Abbreviations:
    ISA
    intrinsic sympathomimetic activity
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    SD
    Sprague-Dawley
    SHHF
    spontaneously hypertensive heart failure
    • Received July 23, 1998.
    • Accepted October 27, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 1
1 Apr 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats

Robert N. Willette, Nambi Aiyar, Tian-Li Yue, Marcus P. Mitchell, Jyoti Disa, Barbara L. Storer, Diane P. Naselsky, Jeffery M. Stadel, Eliot H. Ohlstein and Robert R. Ruffolo
Journal of Pharmacology and Experimental Therapeutics April 1, 1999, 289 (1) 48-53;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

In Vitro and In Vivo Characterization of Intrinsic Sympathomimetic Activity in Normal and Heart Failure Rats

Robert N. Willette, Nambi Aiyar, Tian-Li Yue, Marcus P. Mitchell, Jyoti Disa, Barbara L. Storer, Diane P. Naselsky, Jeffery M. Stadel, Eliot H. Ohlstein and Robert R. Ruffolo
Journal of Pharmacology and Experimental Therapeutics April 1, 1999, 289 (1) 48-53;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Response-Rate Suppression in Operant Paradigm as Predictor of Soporific Potency in Rats and Identification of Three Novel Sedative-Hypnotic Neuroactive Steroids
  • Cannabinol-Mediated Inhibition of Nuclear Factor-κB, cAMP Response Element-Binding Protein, and Interleukin-2 Secretion by Activated Thymocytes
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics